SCHEMBL735690

SCHEMBL735690

COC(=O)[C@H](CCO)N1CCN(c2ccc(OC(F)(F)F)cc2)CCC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 10/20 0.41
KCNA5 P22460 1/20 0.40
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
LIPE Q05469 3/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CACNA1B Q00975 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735691 1.00 CHRM4 (0.41) CHRM4KCNA5PPARDPPARACHRM2
SCHEMBL734488 0.90 NOTUM (0.44) CHRM4CHRM2CHRM1LMNA
SCHEMBL734487 0.90 NOTUM (0.44) CHRM4CHRM2CHRM1LMNA
SCHEMBL733758 0.88 LDHA (0.46) PPARDPPARAMAPTHTT
SCHEMBL733759 0.88 LDHA (0.46) PPARDPPARAMAPTHTT
SCHEMBL734901 0.87 CHRM4 (0.41) CHRM4KCNA5PPARDPPARACHRM2
SCHEMBL734900 0.87 CHRM4 (0.41) CHRM4KCNA5PPARDPPARACHRM2
SCHEMBL735127 0.85 CHRM4 (0.44) CHRM4CHRM2CHRM5CHRM1CHRM3
SCHEMBL735128 0.85 CHRM4 (0.44) CHRM4CHRM2CHRM5CHRM1CHRM3
SCHEMBL734899 0.84 GFER (0.45) ALDH1A1LMNAMAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 CHRM4 83/4885KCNA5 1926/4885PPARD 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.